Remimazolam Tosilate + Propofol Injection.
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Local Anesthesia Assisted Sedation
Conditions
Local Anesthesia Assisted Sedation
Trial Timeline
May 7, 2021 → Jul 4, 2021
NCT ID
NCT05015361About Remimazolam Tosilate + Propofol Injection.
Remimazolam Tosilate + Propofol Injection. is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Local Anesthesia Assisted Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT05015361. Target conditions include Local Anesthesia Assisted Sedation.
What happened to similar drugs?
6 of 20 similar drugs in Local Anesthesia Assisted Sedation were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05015361 | Phase 2 | Completed |
Competing Products
20 competing products in Local Anesthesia Assisted Sedation